Scientist, Lipid Nano Particle Delivery at NewLimit

South San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

BiotechnologyIndustries

Requirements

Ph.D. in Biomedical Engineering, Chemical Biology, Chemical Engineering, or a related discipline or ≥5 years of equivalent industry experience
Experience formulating lipid nanoparticles with diverse lipid components for nucleic acid delivery
Experience evaluating lipid nanoparticle quality based on size, nucleic acid loading efficiency, and polydispersity
Experience with LNP delivery either in vitro or in vivo and associated reporter read-outs

Responsibilities

Collaborate with our Epigenetic Editing and Metabolism teams to design and implement an LNP delivery strategy for reprogramming interventions
Formulate lipid nanoparticles for nucleic acid delivery to hepatocytes in a variety of model systems, including humanized liver models
Engineer lipid nanoparticles with targeting moieties to promote cell type-specific delivery
Serve as the key decision maker for NewLimit’s lipid nanoparticle formulation approach at the Discovery stage
Analyze and interpret experimental data to drive decision making in Discovery and pre-clinical Development

Skills

LNP Formulation

Lipid Nanoparticles

Nucleic Acid Delivery

Hepatocyte Delivery

Targeting Moieties

Particle Size Analysis

Encapsulation Efficiency

Polydispersity Index

Epigenetic Editing

NewLimit

Medicines for healthspan extension via epigenetics

About NewLimit

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, targeting age-related diseases with the goal of creating a new class of medicines that enhance health during aging. The company serves the healthcare market, working with pharmaceutical companies and healthcare providers, and aims to transform aging by developing effective treatments.

South San Francisco, CaliforniaHeadquarters

2022Year Founded

$38.9MTotal Funding

SERIES_ACompany Stage

Biotechnology, HealthcareIndustries

11-50Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Risks

Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.

Ethical concerns and regulatory scrutiny may delay product approvals.

Competition from similar biotech firms could impact NewLimit's market share.

Differentiation

NewLimit focuses on epigenetic reprogramming to extend human healthspan.

The company uses single-cell genomics and machine learning for drug discovery.

NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Upsides

Increased interest in epigenetic reprogramming boosts NewLimit's market potential.

Machine learning aids in identifying novel drug candidates for age-related diseases.

FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

Land your dream remote job 3x faster with AI

Try Jobo Free